Costco vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
NASDAQ: COST warehouse club at $249.6B FY2024 revenue with 73.4M cardholders and $50B+ Kirkland Signature; 90%+ renewal rate with $65/$130 membership fee competing with Sam's Club for warehouse retail.
About
Costco Wholesale Corporation is an Issaquah, Washington-based membership warehouse club — listed on NASDAQ (NASDAQ: COST) — operating 897 warehouse locations globally (as of mid-2025) across the United States, Canada, United Kingdom, Japan, Korea, Australia, Spain, France, China, and Iceland, providing paid members (73.4 million cardholders representing 136.8 million authorized users as of fiscal year end 2024) with bulk merchandise, groceries, electronics, appliances, tires, optical services, pharmacy, and the Kirkland Signature private label brand at prices consistently below traditional retail channels. Costco generated $249.6 billion in total revenue in fiscal year 2024 (ended September 2024, +5% year-over-year), with membership fee revenue of $4.83 billion providing the financial foundation that enables Costco's famously low product margins.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.